Organoid Science, a biotech specializing in organoids, announced on the 28th that it had signed a technology transfer agreement with the Korea Research Institute of Bioscience and Biotechnology. Through this contract, Organoid Science will receive the patented technology for the ESC/iPSC-based intestinal organoid manufacturing method developed by the Korea Research Institute of Bioscience and Biotechnology.
This technology was published in the journal Nature Communications in 2018 by Dr. Miyoung Son’s team at the Korea Research Institute of Bioscience and Biotechnology. It has been registered domestically and applied for in the U.S. as a source patent capable of inducing maturation of intestinal organoids for pluripotent stem cell-based regenerative therapy, and will be widely used in the future. It is a key technology for developing regenerative treatments based on intestinal organoids.
Through this technology transfer, Organoid Science will create an off-the-shelf organoid regeneration therapy by fusing the intestinal organoid differentiation and production technology of Dr. Miyoung Son of the Korea Research Institute of Bioscience and Biotechnology with the company’s autologous organoid treatment technology. It was possible to develop it.
Through this technology transfer, Dr. Miyoung Son’s team at the Korea Research Institute of Bioscience and Biotechnology will transfer the relevant technology, support functional intestinal organoid production technology and standardization (SOP), and collaborate to develop a general-purpose organoid regeneration treatment in the future.
It’s not just this. Through this transfer of high-functional intestinal organoid production technology, Organoid Science has secured technology for evaluating the efficacy, toxicity, and physical properties of various new materials such as new drugs and health functional foods, as well as seeking to dominate the organoid-based drug evaluation market and diversify sales areas. .
Jongman Yoo, CEO of Organoid Science, said, “By securing the core technology to develop clinical-grade, high-efficiency intestinal organoid therapeutics without external gene insertion, this will be the cornerstone of expanding the scope of application of the intestinal organoid therapeutics that we are currently developing.” “We hope that through technology transfer, the two organizations will achieve synergy effects and become the cornerstone of commercialization of organoid treatments.”
Dr. Miyoung Son of the Korea Research Institute of Bioscience and Biotechnology said, “We will continue to cooperate with each other so that Organoid Science can dominate the original technology as a first-in-class regenerative therapy.”
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asia Innovation Hub Pangyo Techno Valley 2022’ news